Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 294

1.

Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.

Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL.

J Natl Cancer Inst. 2018 Dec 17. doi: 10.1093/jnci/djy196. [Epub ahead of print]

PMID:
30561713
2.

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.

Kanjanapan Y, Day D, Butler MO, Wang L, Joshua AM, Hogg D, Leighl NB, Razak ARA, Hansen AR, Boujos S, Chappell M, Chow K, Sherwin B, Stayner LA, Soultani L, Zambrana A, Siu LL, Bedard PL, Spreafico A.

Eur J Cancer. 2018 Dec 6;107:1-7. doi: 10.1016/j.ejca.2018.10.017. [Epub ahead of print]

PMID:
30529898
3.

Immune Biomarkers of Response to Immune-Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma.

Oliva M, Spreafico A, Taberna M, Alemany L, Coburn B, Mesia R, Siu LL.

Ann Oncol. 2018 Nov 21. doi: 10.1093/annonc/mdy507. [Epub ahead of print]

PMID:
30462163
4.

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J.

JAMA Oncol. 2018 Nov 1. doi: 10.1001/jamaoncol.2018.4628. [Epub ahead of print]

PMID:
30383184
5.

Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.

Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O'Callaghan CJ, Jonker DJ, Tu D, Chen E, Morgen E, Price TJ, Shapiro J, Siu LL, Kubo M, Dobrovic A, Ratain MJ, Xu W, Mushiroda T, Liu G.

Cancer Med. 2018 Nov;7(11):5478-5487. doi: 10.1002/cam4.1819. Epub 2018 Oct 14.

6.

When Community Calls, We Collaborate! Community-Based Participatory Research With the Multilanguage Montagnard Refugee Community.

Morrison SD, Sudha S, Young A, Dharod J, Nie YB, Siu HW, Siu L, Ksor HV, Sayers J, Bernot K, Malotky M, Nsonwu M.

Prog Community Health Partnersh. 2018;12(2):179-186. doi: 10.1353/cpr.2018.0038.

PMID:
30270228
7.

Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.

Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, Shalabi A, Siu LL, Tabernero J, Giaccone G; task force on Methodology for the Development of Innovative Cancer Therapies .

Ann Oncol. 2018 Nov 1;29(11):2175-2182. doi: 10.1093/annonc/mdy398.

PMID:
30202892
8.

Additional germline findings from a tumor profiling program.

Stjepanovic N, Stockley TL, Bedard PL, McCuaig JM, Aronson M, Holter S, Semotiuk K, Leighl NB, Jang R, Krzyzanowska MK, Oza AM, Gupta A, Elser C, Ahmed L, Wang L, Kamel-Reid S, Siu LL, Kim RH.

BMC Med Genomics. 2018 Aug 9;11(1):65. doi: 10.1186/s12920-018-0383-5.

9.

Precision Medicine in Head and Neck Cancer: Myth or Reality?

Malone E, Siu LL.

Clin Med Insights Oncol. 2018 Jun 4;12:1179554918779581. doi: 10.1177/1179554918779581. eCollection 2018.

10.

Lung cancer in never smokers from the Princess Margaret Cancer Centre.

Korpanty GJ, Kamel-Reid S, Pintilie M, Hwang DM, Zer A, Liu G, Leighl NB, Feld R, Siu LL, Bedard PL, Tsao MS, Shepherd FA.

Oncotarget. 2018 Apr 27;9(32):22559-22570. doi: 10.18632/oncotarget.25176. eCollection 2018 Apr 27.

11.

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C.

J Clin Oncol. 2018 May 7:JCO2018782292. doi: 10.1200/JCO.2018.78.2292. [Epub ahead of print]

PMID:
29733771
12.

Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort.

Bernstein LJ, Pond GR, Gan HK, Tirona K, Chan KK, Hope A, Kim J, Chen EX, Siu LL, Razak ARA.

Head Neck. 2018 Sep;40(9):2029-2042. doi: 10.1002/hed.25198. Epub 2018 Apr 17.

PMID:
29667262
13.

Rational design and identification of immuno-oncology drug combinations.

Iafolla MAJ, Selby H, Warner K, Ohashi PS, Haibe-Kains B, Siu LL.

Eur J Cancer. 2018 May;95:38-51. doi: 10.1016/j.ejca.2018.02.027. Epub 2018 Apr 7.

PMID:
29631102
14.

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.

Aghajanian C, Bell-McGuinn KM, Burris HA 3rd, Siu LL, Stayner LA, Wheler JJ, Hong DS, Kurkjian C, Pant S, Santiago-Walker A, Gauvin JL, Antal JM, Opalinska JB, Morris SR, Infante JR.

Invest New Drugs. 2018 Dec;36(6):1016-1025. doi: 10.1007/s10637-018-0591-z. Epub 2018 Apr 3.

PMID:
29611022
15.

Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement Summary.

Nekhlyudov L, Lacchetti C, Siu LL.

J Oncol Pract. 2018 Mar;14(3):167-171. doi: 10.1200/JOP.2017.029041. Epub 2017 Dec 19. No abstract available.

PMID:
29257719
16.

Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.

Pezo RC, Chen TW, Berman HK, Mulligan AM, Razak AA, Siu LL, Cescon DW, Amir E, Elser C, Warr DG, Sridhar SS, Yu C, Wang L, Stockley TL, Kamel-Reid S, Bedard PL.

Breast Cancer Res Treat. 2018 Feb;168(1):159-168. doi: 10.1007/s10549-017-4580-2. Epub 2017 Nov 24.

17.

Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer.

Zer A, Pond GR, Razak ARA, Tirona K, Gan HK, Chen EX, O'Sullivan B, Waldron J, Goldstein DP, Weinreb I, Hope AJ, Kim JJ, Chan KKW, Chan AK, Siu LL, Bernstein LJ.

JAMA Otolaryngol Head Neck Surg. 2017 Nov 22. doi: 10.1001/jamaoto.2017.2235. [Epub ahead of print]

18.

Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts.

Brana I, Pham NA, Kim L, Sakashita S, Li M, Ng C, Wang Y, Loparco P, Sierra R, Wang L, Clarke BA, Neel BG, Siu LL, Tsao MS.

Oncotarget. 2017 Jul 8;8(49):84659-84670. doi: 10.18632/oncotarget.19109. eCollection 2017 Oct 17.

19.

The European Society for Medical Oncology (ESMO) Precision Medicine Glossary.

Yates LR, Seoane J, Le Tourneau C, Siu LL, Marais R, Michiels S, Soria JC, Campbell P, Normanno N, Scarpa A, Reis-Filho JS, Rodon J, Swanton C, Andre F.

Ann Oncol. 2018 Jan 1;29(1):30-35. doi: 10.1093/annonc/mdx707.

PMID:
29140430
20.

Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience.

Chiu JW, Krzyzanowska MK, Serra S, Knox JJ, Dhani NC, Mackay H, Hedley D, Moore M, Liu G, Burkes RL, Brezden-Masley C, Roehrl MH, Craddock KJ, Tsao MS, Zhang T, Yu C, Kamel-Reid S, Siu LL, Bedard PL, Chen EX.

Clin Colorectal Cancer. 2018 Mar;17(1):73-79. doi: 10.1016/j.clcc.2017.10.010. Epub 2017 Oct 23.

PMID:
29128266

Supplemental Content

Loading ...
Support Center